Pfizer Inc. stock steady amid Guggenheim target hike to $36 and fresh Lyme vaccine data as analysts maintain buy ratings

Pfizer Inc. stock held steady in recent trading on the NYSE after Guggenheim raised its price target to $36 from $35 while maintaining a buy rating, and Jefferies reaffirmed its buy stance with a $34 target. These updates come alongside Phase 3 data from the Pfizer-Valneva Lyme disease vaccine candidate, which demonstrated over 73% efficacy in reducing infections despite missing a key secondary goal. For US investors, this combination signals potential pipeline upside in vaccines and infectious diseases at a time when Pfizer seeks to diversify beyond COVID-era revenues.

As of: 25.03.2026

Dr. Elena Marquez, Senior Pharma Equity Analyst: Pfizer's vaccine pipeline refresh underscores resilient R&D execution amid patent cliffs, positioning the stock for selective US portfolio allocation.

Analyst Momentum Builds with Guggenheim and Jefferies Updates

Guggenheim's adjustment to a $36 price target reflects confidence in Pfizer's operational trajectory, keeping the buy rating intact as of March 24, 2026. Jefferies analyst Akash Tewari similarly upheld a buy recommendation with a $34 target in a note released around the same time. These moves contrast with the broader analyst consensus of outperform and an average target of $28.54 based on 28 analysts, implying about 6.62% upside from the recent NYSE close of $26.77 USD.

The Pfizer Inc. stock was last seen on NYSE at $26.77 USD, down 0.74% in the prior session, with pre-market activity showing minor fluctuations around $26.80 USD. Such target hikes typically bolster investor sentiment in pharma, where pipeline milestones and cost discipline drive valuations. US investors tracking dividend aristocrats will note Pfizer's established yield profile alongside these updates.

Lyme Vaccine Phase 3 Data Sparks Pipeline Debate

Pfizer and partner Valneva announced on March 23, 2026, that their Lyme disease vaccine candidate LB6V showed strong efficacy of over 73% in preventing infections in a Phase 3 Valor trial. The vaccine was well-tolerated with no major safety concerns identified. While it missed a key secondary endpoint, the primary results position it as a potential first-in-class option for Lyme prevention, a significant US health issue with over 476,000 estimated annual cases.

For Pfizer, this data revives momentum in its vaccines portfolio post-COVID, targeting a market long underserved by prophylactic options. US investors should monitor FDA feedback, as Lyme's endemic prevalence in the Northeast and Midwest creates domestic reimbursement tailwinds. The news contributed to sector rotation in health care stocks amid broader market dynamics.

Mini-Tender Warning Highlights Shareholder Vigilance

Pfizer issued a warning against an unsolicited mini-tender offer at $32 per share on the NYSE, urging shareholders to reject it. These offers often seek small stakes below market value, posing risks to retail investors. Amid the stock's $26.77 USD NYSE close, the $32 bid appears premium but lacks full regulatory backing typical of tender offers.

US investors, particularly retail holders, benefit from such corporate alerts, which reinforce governance standards. This episode coincides with price target optimism, reminding stakeholders of liquidity and takeover speculation in undervalued pharma names. Pfizer's 75,000 employees and global footprint underscore its scale against such tactics.

US Investor Relevance in a Post-Patent Landscape

With 60.8% of net sales from the United States, Pfizer remains a core holding for US investors seeking pharma exposure. Primary care (47.4%), specialty care (26.2%), and oncology (24.5%) segments drive revenues, bolstered by mRNA tech and antivirals. The Lyme data taps into domestic infectious disease needs, potentially accelerating approvals and uptake in high-prevalence regions.

Analyst upgrades signal undervaluation relative to peers, with Pfizer's ESG MSCI A rating appealing to sustainable portfolios. For dividend-focused US investors, the stock's history provides stability amid volatility in growth biotechs. Sector rotation into health care on March 23 further highlights tactical opportunities.

Pipeline Risks and Secondary Endpoint Miss

The Lyme vaccine's miss on a key secondary goal introduces regulatory uncertainty, as FDA scrutiny on endpoints could delay filings. Valneva shares fell sharply, but Pfizer's diversified portfolio mitigates single-asset risk. Investors weigh this against strong primary efficacy and safety data.

Open questions include commercialization timelines and competition from emerging tick-borne therapies. Patent expirations on blockbusters like Eliquis remain a headwind, pressuring margins unless offset by launches. US reimbursement dynamics will prove pivotal for Lyme vaccine economics.

Broader Sector Context and Valuation Outlook

Pfizer's trader and investor ratings reflect solid fundamentals and EPS visibility. Consensus spread suggests modest upside, but buy ratings from key firms indicate selective optimism. Health care's modest gains amid cyclical rotation position Pfizer as a defensive play with growth levers.

For US investors, balancing pipeline catalysts against macro pressures like drug pricing reforms favors patient accumulation. The NYSE-traded stock's liquidity supports institutional flows, with pre-market stability signaling measured reaction to news flow.

Disclaimer: This is not investment advice. Stocks are volatile financial instruments.